Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VaxGen, Raven to merge

After market close, VXGN and Raven (South San Francisco, Calif.) said they will merge in a stock deal. Raven stockholders will receive 32 million

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE